S&P 500   2,998.36 (+1.09%)
DOW   27,046.61 (+0.97%)
QQQ   193.37 (+1.19%)
AAPL   235.62 (-0.11%)
FB   189.77 (+3.54%)
MSFT   141.38 (+1.31%)
AMZN   1,758.54 (+1.27%)
CGC   19.88 (+5.41%)
NVDA   196.85 (+5.53%)
MU   46.29 (+3.19%)
AMD   30.64 (+0.36%)
T   37.90 (+1.15%)
ACB   3.75 (+6.83%)
GILD   65.51 (+1.55%)
S&P 500   2,998.36 (+1.09%)
DOW   27,046.61 (+0.97%)
QQQ   193.37 (+1.19%)
AAPL   235.62 (-0.11%)
FB   189.77 (+3.54%)
MSFT   141.38 (+1.31%)
AMZN   1,758.54 (+1.27%)
CGC   19.88 (+5.41%)
NVDA   196.85 (+5.53%)
MU   46.29 (+3.19%)
AMD   30.64 (+0.36%)
T   37.90 (+1.15%)
ACB   3.75 (+6.83%)
GILD   65.51 (+1.55%)
Log in

Magenta Therapeutics Stock Price, News & Analysis (NASDAQ:MGTA)

$9.91
+0.13 (+1.33 %)
(As of 10/15/2019 12:02 PM ET)
Today's Range
$9.75
Now: $9.91
$10.03
50-Day Range
$9.48
MA: $10.37
$11.80
52-Week Range
$5.31
Now: $9.91
$21.00
Volume1,223 shs
Average Volume52,805 shs
Market Capitalization$389.86 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13
Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTA
CUSIPN/A
CIKN/A
Phone857-242-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.39 per share

Profitability

Net Income$-57,510,000.00

Miscellaneous

Employees59
Market Cap$389.86 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.


Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics Inc (NASDAQ:MGTA) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.01. View Magenta Therapeutics' Earnings History.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Magenta Therapeutics.

What price target have analysts set for MGTA?

4 Wall Street analysts have issued 1 year target prices for Magenta Therapeutics' stock. Their forecasts range from $16.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price. View Analyst Price Targets for Magenta Therapeutics.

What is the consensus analysts' recommendation for Magenta Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Magenta Therapeutics.

Has Magenta Therapeutics been receiving favorable news coverage?

Media headlines about MGTA stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Magenta Therapeutics earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Magenta Therapeutics.

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the folowing people:
  • Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)
  • Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)
  • Ms. Alison Lawton, Board Advisor (Age 58)
  • Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)
  • Ms. Manisha Pai, VP of Investor Relations & Communications

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $9.81.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $385.93 million. The company earns $-57,510,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe.View Additional Information About Magenta Therapeutics.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is http://www.magentatx.com/.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]


MarketBeat Community Rating for Magenta Therapeutics (NASDAQ MGTA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote "Outperform" if you believe MGTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Gap Down Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel